Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer

Medical Oncology

Volumn 21, Issue 3, 2004, Pages 255-262

  Benavides, Manuel ^a   Garcia Alfonso P ^b   Cobo, M ^a   Munoz Martin A ^b   Gil Calle, S ^a   Cambantes, F ^a   Villar, E ^a   Graupera, J ^c   Balcells, M ^c   Perez Manga G ^b  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c Prasfarma Almirall Prodesfarma ^*  (Spain)

Author keywords

Advanced CRC; CPT 11; Heavily pretreated; Poor performance status; Weekly schedule

Indexed keywords

FLUOROURACIL; IRINOTECAN; RALTITREXED; UFT;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RETREATMENT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEUTROPENIA; PROSPECTIVE STUDIES; SAFETY; TIME FACTORS;

EID: 7944231989     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:21:3:255     Document Type: Article

References (15)

1. Shimada Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11(5):909-913.
2. Rougier P, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997;15(1):251-260.
3. Pilot HC, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997;15(8): 2910-2919.
4. Rothenberg ML, et al. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 1999;85(4):786-795.
5. Cunningham D, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352(9138):1413-1418.
6. Rougier P, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352(9138):1407-1412.
7. Douillard JY, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355(9209):1041-1047.
8. Saltz LB, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343(13):905-914.
9. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47(1):207-214.
10. National Cancer Institute: Guidelines for the reporting of adverse drug reactions. MD, Division of Cancer Treatment, National Cancer Institute 1999:1-80.
11. Roila F, et al. Intra- and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 1991;2(6):437-439.
12. Verger E, Salamero M, Conill C. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? Eur J Cancer 1992;28A(8-9):1328-1330.
13. Fuchs CS, et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 2003;21(5):807-814.
14. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998;16(1):301-308.
15. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysts Group In Cancer. J Clin Oncol 1998;16(11):3537-3541.